Dublin, Ireland, December 12, 2022 - RemedyBio, an immune therapy discovery and development biotech company,…
Remedy BiologicsDecember 13, 2022
EU Programme funded under Horizon Europe Developing a ground-breaking inhaled gene therapy for lung cancer…
Remedy BiologicsDecember 6, 2022
Primary tissue material to be supplied by Brigham and Women’s Hospital and Dana-Farber Cancer Institute…
Remedy BiologicsOctober 10, 2022
Strengthening target and drug discovery expertise with the addition of Dr Christopher Miller Dublin, Ireland,…
Remedy BiologicsSeptember 8, 2022
Initial focus on patient derived TILs in gynaecological cancers RemedyBio will collaborate with researchers at…
Remedy BiologicsJune 6, 2022
Leading experts in immunology, immuno-oncology and cancer cell therapies bring their expertise to advance development…
Remedy BiologicsMay 25, 2022
RemedyBio today announces a new collaborative research project with the Thoracic Oncology Research Group (TORG) at…
Remedy BiologicsNovember 24, 2021
The European Innovation Council Fund supports RemedyBio with an €8M investment facility adding to EIC’s…
Remedy BiologicsJuly 20, 2021
RemedyBio today announced that Mr. Ashley Nagle has joined the company as Vice President, Business Development. Mr.…
Remedy BiologicsMay 21, 2021
RemedyBio is delighted to announce the success of the HEALED Consortium in securing DTIF support…
Remedy BiologicsApril 23, 2021